通过组合图书馆查识别阿尔茨海默病的候选IgG生物标志物
M Muralidhar Reddy1, Rosemary Wilson, Johnnie Wilson
1Opko Health Laboratories, Jupiter, FL 33458, USA.
Cell
|January 11, 2011
概括
研究人员开发了一种新方法,在不需要识别抗原的情况下找到疾病生物标志物. 这种方法将合成分子与患者样本进行选,成功识别了阿尔茨海默病和多发性硬化症的潜在生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
- 蛋白质组学是指蛋白质组学.
背景情况:
- 适应性免疫系统是蛋白质生物标记物的有希望的来源.
- 鉴定诊断有用的抗体受到许多疾病中引发免疫反应的未知抗原的阻碍.
研究的目的:
- 提出一种一般的,公正的方法来识别诊断有用的抗体.
- 克服要求先前对抗原进行识别的局限性.
主要方法:
- 合成分子组合图书馆与病例和对照的血清样本进行比较选.
- 识别与对照组相比,从疾病病例中结合的IgG抗体显著更多的分子.
- 测试确定分子作为诊断有用的抗体的捕获剂.
主要成果:
- 在多发性硬化症的小鼠模型中证明了实用性.
- 确定了阿尔茨海默病的两种候选IgG生物标志物.
结论:
- 提出的方法为生物标志物发现提供了一种新的策略.
- 这种方法有助于在没有先前的抗原知识的情况下识别出诊断上有用的抗体.
- 这些发现突出了像阿尔茨海默氏症这样的神经退行性疾病的潜在新生物标志物.
更多相关视频
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
9.3K
05:25Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023
2.5K
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38